Merck (NYSE: MRK) has signed seven non-exclusive voluntary licensing agreements with generic manufacturers for alimatravir (MK-8527), an investigational once-monthly oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE